Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | Unknown unknown |
Therapy | Cytarabine + Daunorubicin + Glasdegib |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | not applicable |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | acute myeloid leukemia | not applicable | Cytarabine + Daunorubicin + Glasdegib | Phase Ib/II | Actionable | In a Phase Ib trial, the combination of Glasdegib (PF-04449913), Cytosar-U (cytarabine), and Cerubidine (daunorubicin) resulted in an overall survival of 34.7 months in patients with either acute myeloid leukemia (AML) or myelodysplastic syndrome, with 55% (11/20) of AML patients experiencing a complete remission (PMID: 29463550). | 29463550 |
PubMed Id | Reference Title | Details |
---|---|---|
(29463550) | Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. | Full reference... |